Before getting to know Hengrui Pharma, let's take a look at the list of leading stocks in the pharmaceutical industry I compiled, and click it to get: Treasure Information: List of Leading Stocks in the Pharmaceutical Industry.
First, from the company's point of view.
Hengrui Pharma's main business is drug research and development, production and sales. The company is not only one of the largest research and production bases of anti-tumor drugs in China, but also one of the research and production bases of surgical drugs and contrast agents. The company's products cover many fields, such as anti-tumor drugs, surgical anesthesia drugs, special infusion, contrast agents, cardiovascular drugs and so on. The product layout has also reached a perfect level. In the fields of anti-tumor, surgical anesthesia, contrast agent, etc. The market share is second to none in the industry.
Next, introduce some advantages of the company ~
Advantage 1: Optimize product structure and promote performance growth.
The company's income structure is now on the next level. To some extent, the growth in the performance of the innovative drug industry has made up for the decrease in the income of the generic drug business. In the field of innovative drug business, the sales of innovative drugs have steadily increased, which is conducive to stimulating the company's performance growth and further updating the company's income structure. The company further increased its investment in R&D and its overseas R&D layout.
Advantage 2: Strengthen R&D and consolidate the company's leading position.
The company has invested more and more money in R&D expenses. During the reporting period, the company spent 2,580,508,300 yuan on R&D, an increase of 38.48% over the same period of last year, accounting for 65,438+09,4438+0% of the company's sales revenue. At present, the company has 16 important product research progress, and 8 projects have entered the clinical phase III trial. During the reporting period, the company obtained 14 product registration approvals, including 5 approvals for innovative drugs and 9 approvals for generic drugs; Get 4 1 clinical approval; Obtain 10 conformity evaluation approval. In the future, the company's innovative product pipeline is expected to continue to enrich, fix its leading position in innovation and improve its market competitiveness.
Advantage 3: The international layout continues to advance.
The company's first international multi-center phase III clinical study, the international multi-center phase III study of Karezumab combined with apatinib in the treatment of advanced liver cancer, has been completed overseas, and the preparations before the US FDA submitted BLA/NDA have been started. With the continuous promotion of the company's internationalization strategy, the communication and cooperation between the company's R&D team and the domestic team has gradually deepened, and the company's overseas business scope has been continuously expanded, which has great opportunities to further expand the advantages of R&D, improve its own innovative products and promote the company's performance in a good direction. In the future, the company will gradually move from "China New" to "Global New" and is expected to grow into a multinational pharmaceutical platform with international competitiveness.
Due to the limited space, I have compiled the detailed contents of Hengrui Pharma's in-depth report and risk warning in this research report. Click to view: comment on the in-depth research report in Hengrui Pharma, and suggest collecting it!
Second, from the perspective of industry.
The fundamentals of the industry are good, and the aging population and consumption upgrading bring rigid demand, which is really good in the long run:
(1) policy: intensive introduction of policies, normalization of quantity procurement, continuous acceleration of industry differentiation, and forced enterprises to transform into innovation; The dynamic adjustment of the relevant medical insurance catalogue has been established, and the R&D innovation of the industry should be vigorously promoted in policy. China's medical innovation has entered a golden period, and the road to internationalization has been opened.
(2) Consumption upgrade: With the continuous growth of China's economic level, the pharmaceutical industry has ushered in the development opportunity of consumption upgrade demand, and the prosperity of the drug segmentation field such as vaccines, which has self-consumption attributes and evades the medical insurance fee control policy, continues.
Third, summary.
Generally speaking, I think Hengrui Pharma Company, as the leading enterprise of innovative drugs in the pharmaceutical industry, is expected to usher in rapid development at the time of industry reform. However, considering that the publication of the article takes time, there is a certain lag. If you want to know the future market of Hengrui Pharma more accurately, don't regret clicking the link. A professional consultant will help you check the stock market and see if the current market in Hengrui Pharma can be bought or sold. Is there any chance to test Hengrui Pharma for free?
Reply time: 202 1-08-26. The latest business changes are subject to the data displayed in the link in the article. Please click to view.